secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sio Gene Therapies Inc. (—)
CIK:        0001636050
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001636050-23-000011
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Sio Gene Therapies receives Nasdaq delisting notice; will not appeal due to planned dissolution
--------------------------------------------------------------------------------

- Nasdaq notified Sio on March 14, 2023, that common stock will be delisted for failure to meet minimum bid price requirement.
- Company will not appeal the delisting determination in light of its planned complete liquidation and dissolution.
- Trading of Sio's common stock expected to be suspended at the open on March 23, 2023; Form 25-NSE to be filed.
- Dissolution plan is pending stockholder approval via proxy statement filed February 21, 2023, with SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636050/000163605023000011/0001636050-23-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636050/000163605023000011/siox-20230314.htm
  HTML page:      https://secwatch.observer/filing/0001636050-23-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer